表紙
市場調查報告書

報告套組 - 競爭企業分析:癌症免疫 & 其他疾病的雙特異性抗體,與T細胞及NK (自然殺手) 細胞結合的雙特異性抗體 (2019年):商務,相關利益者,技術及開發平台分析

2 Reports Bundle - Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases plus T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis

出版商 La Merie Publishing 商品編碼 890416
出版日期 內容資訊 英文
訂單完成後即時交付
價格
報告套組 - 競爭企業分析:癌症免疫 & 其他疾病的雙特異性抗體,與T細胞及NK (自然殺手) 細胞結合的雙特異性抗體 (2019年):商務,相關利益者,技術及開發平台分析 2 Reports Bundle - Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases plus T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis
出版日期: 2019年06月30日內容資訊: 英文
簡介

本報告套組,提供「與T細胞及NK (自然殺手) 細胞結合的雙特異性抗體 (2019年):商務,相關利益者,技術及開發平台分析」其競爭企業分析「癌症免疫 & 其他疾病的雙特異性抗體」相關的系統性資訊。

競爭企業分析:癌症免疫 & 其他疾病的雙特異性抗體

第1章 T細胞重定向雙特異性抗體

  • BCMA標的
  • CD20標的
  • CD19標的
  • CD33標的
  • CD123標的
  • PSMA標的
  • Her2標的
  • Mesothelin標的
  • CD38標的
  • EGF-R標的
  • DLL3 等

第2章 雙特異性自然殺手 (NK) 細胞重定向抗體

第3章 雙特異性T細胞Engaging,有條件共刺激抗體

第4章 雙特異性癌症免疫抗體

第5章 把雙特異性腫瘤相關抗原 (TAA):抗體做為標的成長要素

  • Her2標的
  • VEGF標的
  • 其他TAA標的

第6章 對癌症以外的症狀的雙特異性抗體

  • 發炎性、自體免疫性疾病
  • 心臟代謝性疾病
  • 眼科疾病
  • 神經性疾病
  • 感染疾病
  • 有目標的給藥

與T細胞及NK (自然殺手) 細胞結合的雙特異性抗體 (2019年):商務,相關利益者,技術及開發平台分析

第1章 摘要整理

第2章 簡介

第3章 主要醫藥品企業的相關利益者、技術分析

第4章 技術企業的相關利益者、技術分析

  • 使用結合雙特異性抗體的Ig (免疫球蛋白) 型T細胞或NK細胞的技術企業
  • 使用結合雙特異性抗體的Fc型T細胞或NK細胞的技術企業
  • 使用結合雙特異性抗體的黏合劑型T細胞或NK細胞的技術企業
  • 使用結合雙特異性抗體的特殊T細胞或NK細胞的技術企業

第5章 結合雙特異性抗體的T細胞及NK細胞的開發平台分析

  • 腫瘤標的 & 效應器細胞的結合
  • 使用以結合T細胞的雙特異性抗體為標的之BCMA的臨床試驗
  • 使用以結合T細胞的雙特異性抗體為標的之CD33的臨床試驗
  • 使用以變更T細胞的雙特異性抗體為標的之CD20的臨床試驗
  • 使用以結合T細胞的雙特異性抗體為標的之CD123的臨床試驗
  • 使用以結合T細胞的雙特異性抗體為標的之PSMA的臨床試驗
  • 目標與下面及其他固態腫瘤的臨床試驗結合T細胞的雙特異性抗體
  • 目標與下面及其他血液癌症的臨床試驗結合T細胞的雙特異性抗體
  • 變更中止的雙特異性抗體的臨床階段的T細胞

第6章 技術企業的資金來源、聯盟契約

第7章 企業簡介

第8章 技術簡介

第9章 醫藥品、醫藥品候補藥的簡介

第10章 參考資料

目錄
Product Code: LMFR0029

This report package includes the full report:

  • T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

and the Competitor Analysis report:

  • Bispecific Antibodies for Immuno-Oncology & Other Diseases

The full report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019. The report brings you up-to-date information about major pharmaceutical and technology companies active in the field, state of the art and emerging next generation technologies, subject and economic terms of partnering deals and a pipeline analysis of product candidates including clinical experiences.

Analysis is based on the profiles of 56 Big Pharma and technology companies covering company background/history, financial situation, technology overview, partnering activities and pipeline overviw. 38 different technologies to create bispecific T-cell and NK cell engaging antibodies are profiled in depth. Pipeline analysis is based on the profiles of 90 drug candidates in development. Sources of information are 237 scientific references. Non-scientific sources of information, such as press releases, annual reports and presentations, are disclosed within the text with an embedded hyperlink leading to the online source of information.

The Competitor Analysis report about Bispecific Antibodies for Immuno-Oncology & Other Diseases evaluates the landscape of investigational bispecific therapeutic antibodies for treatment of cancer, inflammatory & autoimmune diseaseas as well as cardiometabolic, infectious, neurologic and ophthalmic diseases as of June 2019. Results are presented in a tabular format.

At present, only two bispecific therapeutic monoclonal antibodies are on the market, one for leukemia and one for hemophilia. La Merie Publishing conducted a search for bispecific monoclonal antibodies (and some multimeric proteins) in R&D. The search identified 271 unique bispecific antibody-based constructs in active R&D (excluding discontinued developments of bispecifics). Of the 110 clinical stage bispecific antibodies, 50% are used for redirection of T-cells to a tumor target. More than 85% of the clinical stage bispecific molecules are in development for treatment of cancer. The combination of immune checkpoint inhibitor and/or activator targets is a strongly emerging use of the bispecific antibody technology. The traditonal application of bispecifics for targeting two tumor-associated antigens (or epitopes) and/or growth factors is a field with strong clinical activities, but the non-clinical pipeline is relatively empty compared with immuno-oncology bispecifics (11 vs 48 projects).

Table of Contents

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

1) T-Cell Redirecting Bispecific Antibodies

  • Targeting BCMA
  • Targeting CD20
  • Targeting CD19
  • Targeting CD33
  • Targeting CD123
  • argeting PSMA
  • Targeting Her2
  • Targeting Mesothelin
  • Targeting CD38
  • Targeting EGF-R
  • Targeting DLL3
  • Targeting Various Other Cancer Surface Antigens
  • Targeting Not Disclosed Tumor Associated Antigens
  • Targeting (Intracellular) peptide/MHC Antigens
  • Novel Bispecific T-Cell Redirecting Antibody Constructs
  • Bispecific T-Cell Redirecting Antibodies for Infectious & Other Diseases

2) Bispecific Natural Killer (NK) Cell Redirecting Antibodies

3) Bispecific T-Cell Engaging, Conditional Costimulatory Antibodies

  • Bispecific, Tumor-Targeted, Conditional 4-1BB Costimulatory Antibodies
  • Bispecific, Tumor-Targeted, Conditional CD40 Costimulatory Antibodies
  • Bispecific, Tumor-Targeted, Conditional CD28 or OX40 Costimulatory Antibodies
  • Bispecific, Dual Costimulatory Antibodies

4) Bispecific Immuno-Oncology Antibodies

  • Bispecific, Tumor-Targeted Checkpoint Inhibitor Antibodies
  • Bispecific Checkpoint Inhibitor & Costimulator Antibodies
  • Bispecific CD47 Tumor Microenvironment (TME) Targeted Antibodies
  • Other Bispecific, Tumor Microenvironment (TME) Targeted Antibodies
  • Bispecific, Dual PD-1 & PD-L1 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-1/PD-L1 & CTLA-4 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-1 & LAG-3 Checkpoint Inhibitor Antibodies
  • Bispecific, Dual PD-L1/CTLA-4 & LAG-3 Checkpoint Inhibitor Antibodies
  • Bispecific, PD-1/PD-L1/CTLA-4 & TIM-3 or GITR Checkpoint Inhibitor Antibodies
  • Bispecific, Not Specified Immuno-Oncology Antibodies

5) Bispecific Tumor Associated Antigen (TAA) / Growth Factor Targeted Antibodies

  • Bispecific Her2-Targeted Antibodies
  • Bispecific VEGF-Targeted Antibodies
  • Other Bispecific TAA-Targeted Antibodies

6) Bispecific Antibodies for Non-Cancer Indications

  • Bispecific Inflammatory & Autoimmune Disease Antibodies
  • Bispecific Cardiometabolic Antibodies
  • Bispecific Ophthalmic Disease Antibodies
  • Bispecific Neurologic Disease Antibodies
  • Bispecific Infectious Disease Antibodies
  • Bispecific Antibodies For Targeted Delivery

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

1. Executive Summary

2. Introduction

3. Stakeholder and Technology Analysis of Major Pharmaceutical Companies

4. Stakeholder and Technology Analysis of Technology Companies

  • 4.1. Technology Companies with Ig-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies
  • 4.2. Technology Companies with Fc-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies
  • 4.3. Technology Companies with Binder-Based T-cell or NK Cell Engaging Bispecific Antibody Technologies
  • 4.4. Technology Companies with Special T-cell or NK Cell Engaging Bispecific Antibody Technologies

5. Pipeline Analysis of T-Cell and NK Cell Engaging Bispecific Antibodies

  • 5.1. Tumor Targetin. Effector Cell Engagement
  • 5.2. Clinical Experience with BCMA-Targeted T-Cell Engaging Bispecific Antibodies
  • 5.3. Clinical Experience with CD33-Targeted T-Cell Engaging Bispecific Antibodies
  • 5.4. Clinical Experience with CD20-Targeted T-cell Redirecting Bispecific Antibodies
  • 5.5. Clinical Experience with CD123-Targeted T-Cell Engaging Bispecific Antibodies
  • 5.6. Clinical Experience with PSMA-Targeted T-Cell Engaging Bispecific Antibodies
  • 5.7. Clinical Experience with Other Solid Tumor Targeted T-Cell Engaging Bispecific Antibodies
  • 5.8. Clinical Experience with Other Blood Cancer Targeted T-Cell Engaging Bispecific Antibodies
  • 5.9. Discontinued Clinical Stage T-Cell Redirecting Bispecific Antibodies

6. Sources of Financing and Partnering Deals of Technology Companies

7. Company Profiles

  • 7.1. Major Pharmaceutical Companies with Bispecific T-Cell or NK Cell Engaging Antibodies
  • 7.2. Technology Companies with Ig-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
  • 7.3. Technology Companies with Fc-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
  • 7.4. Technology Companies with Binder-Based Bispecific T-Cell or NK Cell Engaging Antibody Technologies
  • 7.5. Technology Companies with Special Bispecific T-Cell or NK Cell Engaging Antibody Technologies
    • AbbVie
    • Abpro
    • Adimab
    • Affimed Therapeutics
    • Alligator Bioscience
    • Amgen
    • Amphivena Therapeutics
    • Aptevo Therapeutics
    • Arbele
    • Astellas Pharma
    • AstraZeneca
    • BenHealth Biopharmaceuticals
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • Crescendo Biologics
    • CytomX Therapeutics
    • Dragonfly Theraputics
    • Eli Lilly
    • GEMoaB Monoclonals
    • Generon
    • Genmab
    • GlaxoSmithKline
    • Glenmark Pharmaceuticals
    • GT Biopharma
    • Harpoon Therapeutics
    • IGM Biosciences
    • Immatics Biotechnologies
    • Immunocore
    • Innate Pharma
    • Inovio Pharmaceuticals
    • Janssen
    • Lava Therapeutics
    • MacroGenics
    • Maverick Therapeutics
    • Merc. Co.
    • Merus
    • Mogam Institute for Biomedical Research (MIBR)
    • Molecular Partners
    • NJCTTQ
    • Novartis
    • Numab
    • Pfizer
    • Pieris Pharmaceuticals
    • PsiOxus Therapeutics
    • Regeneron Pharmaceuticals
    • Revitope Oncology
    • Roche
    • Sanofi
    • Servier
    • Takeda Pharmaceutical Co.
    • TeneoBio
    • VBL Therapeutics
    • Xencor
    • YZY Biopharma
    • Zymeworks

8. Technology Profiles

  • 8.1. Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • 8.2. Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • 8.3. Binder Only-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologie
  • 8.4. Novel "Special" T-Cell and NK Cell Engaging Bispecific Antibody Technologies
    • ADAPTIR Bispecific, Modular Protein Technology
    • Anticalin Technology
    • ART-Ig Technology
    • Asymmetric head-to-tail 2+1 T-Cell Bispecific (2+1 TCB) IgG antibody platform
    • Azymetric Platform
    • BEAT Technology: Bispecific Engagement by Antibodies based on th. Cell Receptor
    • Biclonics Technology
    • Bispecific IgM Antibodies
    • COBRA Technology
    • CODV-Ig Technology
    • DARPin Multispecifics
    • DNA-Encoded Bi-specifi. Cell Engagers (dBiTEs)
    • DuoBody Technolog
    • DVD-Ig Bispecific Antibody Technology
    • GammaDelta T-cell Engager Platform
    • HLE-BiTE Bispecifi. Cell Engager Technology
    • Humabody Technology
    • Human Heavy Chain Antibody (UniAb) Platform for Bispecifics
    • ImmunoTherapy Antibody (ITab) technology platform
    • ITE Technology
    • Knobs-into-holes Technology
    • MATCH Technology
    • MultiMab Technology with TetraBi Format
    • NK Cell Engager (NKCE) Technology
    • ROCK Platform: Redirected Optimized Cell Killing
    • RUBY Technology
    • T cell Engaging Antibody Circuits (TEACs)
    • T cell-engaging Bispecific Probody Technology
    • T-Cell Engaging Full Length Bispecific Antibody Platform
    • TCER: Bispecific T-cell Engaging Receptor Molecules
    • TCR-based ImmTAC Technology
    • TriKE and TetraKE Technologies
    • TriNKET Technology
    • TriTA. ProTriTAC Technologies
    • Tumor-Specific Immuno-Gene Therapy (T-SIGn)
    • Veloci-Bi Technology
    • XmAb Bispecific Fc Technology
    • YBody Bispecific Antibody Technology

9 Drug and Drug Candidate Profiles

  • 9.1.1. A-319
  • 9.1.2. A-337
  • 9.1.3. ABBV-428
  • 9.1.4. ABP-100
  • 9.1.5. ABP-110
  • 9.1.6. ABP-150
  • 9.1.7. AFM13
  • 9.1.8. AFM14
  • 9.1.9. AFM26
  • 9.1.10. ALG.APV-527
  • 9.1.11. AMG 160
  • 9.1.12. AMG 212
  • 9.1.13. AMG 330
  • 9.1.14. AMG 420
  • 9.1.15. AMG 424
  • 9.1.16. AMG 427
  • 9.1.17. AMG 562
  • 9.1.18. AMG 596
  • 9.1.19. AMG 673
  • 9.1.20. AMG 701
  • 9.1.21. AMG 757
  • 9.1.22. AMV564
  • 9.1.23. Anti-FLT3
  • 9.1.24. Anti-ROR1
  • 9.1.25. APVO436
  • 9.1.26. ARB-201
  • 9.1.27. Blincyto
  • 9.1.28. BMS-986277
  • 9.1.29. CB307
  • 9.1.30. CC-93269
  • 9.1.31. ERY974
  • 9.1.32. GBR1302
  • 9.1.33. GBR1342
  • 9.1.34. GBR1372
  • 9.1.35. GEM3PSCA
  • 9.1.36. GEM333
  • 9.1.37. GEN3013
  • 9.1.38. HPN217
  • 9.1.39. HPN328
  • 9.1.40. HPN424
  • 9.1.41. HPN536
  • 9.1.42. IGM2323
  • 9.1.43. IMC-C103C
  • 9.1.44. IMC-F106C
  • 9.1.45. IMCgp100
  • 9.1.46. IMCnyeso
  • 9.1.47. IPH61
  • 9.1.48. JNJ-63709178
  • 9.1.49. JNJ-6389808
  • 9.1.50. JNJ-64007957
  • 9.1.51. JNJ-64407564
  • 9.1.52. JNJ-67571244
  • 9.1.53. M701
  • 9.1.54. M802
  • 9.1.55. MCLA-117
  • 9.1.56. MCLA-145
  • 9.1.57. MG1122
  • 9.1.58. MGD006
  • 9.1.59. MGD007
  • 9.1.60. MGD009
  • 9.1.61. MGD014
  • 9.1.62. MO0310
  • 9.1.63. ND021
  • 9.1.64. NG-641
  • 9.1.65. OXS-1615
  • 9.1.66. OXS-3550
  • 9.1.67. OXS-C3550
  • 9.1.68. PF-06671008
  • 9.1.69. PF-06863135
  • 9.1.70. PRS-342
  • 9.1.71. REGN1979
  • 9.1.72. REGN4018
  • 9.1.73. REGN5458
  • 9.1.74. RG6026
  • 9.1.75. RG6160
  • 9.1.76. RG6194
  • 9.1.77. RG7802
  • 9.1.78. RG7827
  • 9.1.79. RG7828
  • 9.1.80. SAR440234
  • 9.1.81. TNB-383B
  • 9.1.82. TNB-486
  • 9.1.83. TNB-585
  • 9.1.84. TSA(1)-CD2. TSA(2)-CD28
  • 9.1.85. VB-600
  • 9.1.86. XmAb13676
  • 9.1.87. XmAb14045
  • 9.1.88. XmAb18087
  • 9.1.89. XmAb23104
  • 9.1.90. Y111

10. References

List of Tables

  • Table 1: Big Pharma's In-House and In-Licensed T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
  • Table 2: Big Pharma's Preferences for T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
  • Table 3: Big Pharma's Preferences for Half-Life Extension in T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • Table 4: Big Pharma's Preferred Targets for T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • Table 5: Economic Terms of Big Pharma's Collaboratio. Licensing Agreements for T-Cel. NK Cell Engaging Bispecific Antibody Technologies
  • Table 6: Main Characteristics of Big Pharma's T-cell Engaging Bispecific Antibody Technologies
  • Table 7: Safety and Effector Cell Features of Big Pharma's T-cell Engaging Bispecific Antibody Technologies
  • Table 8: Overview of Applied Technology, Target and Highest R&D Phase of Big Pharma's Proprietary T-cell and NK Cell Engaging Bispecific Antibodies
  • Table 9: Overview of Technology Companies with T-Cell and NK-Cell Engaging Bispecific Antibody Technologies
  • Table 10: Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Ig-Based T-Cell or NK Cell Engaging Bispecific Technologies
  • Table 11: Overview of Targets and Highest R&D Phase of Ig-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
  • Table 12: Overview of Partnering Deals of Technology Companies with Ig-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • Table 13: Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Fc-Based T-Cell or NK Cell Engaging Bispecific Technologies
  • Table 14: Overview of Targets and Highest R&D Phase of Fc-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
  • Table 15: Overview of Partnering Deals of Technology Companies with Fc-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • Table 16: Overview of Technology Companies for Safety Features and Mode of Cell Engagement of Binder-Based T-Cell or NK Cell Engaging Bispecific Technologies
  • Table 17: Overview of Targets and Highest R&D Phase of Binder-based T-Cell and NK Cell Engaging Antibodies from Technology Companies
  • Table 18: Overview of Partnering Deals of Technology Companies with Binder-Based T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • Table 19: Overview of Special Technology Companies for Safety Features and Mode of Cell Engagement of T-Cell or NK Cell Engaging Bispecific Technologies
  • Table 20: Overview of Targets and Highest R&D Phase of Various T-Cell and NK Cell Engaging Antibodies from Technology Companies
  • Table 21: Overview of Partnering Deals of Technology Companies with Various T-Cell and NK Cell Engaging Bispecific Antibody Technologies
  • Table 22: Overview of Drug Profiles for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase
  • Table 23: Overview of Not Profiled Drug Candidates for Drug Code, Target, Technology, Company, Indication and Highest R&D Phase
  • Table 24: Tumor Target, Effector Cell Engagement, Tumor Type and Number of Bispecific Antibodies per Phase of T-Cell and NK Cell Engaging Bispecific Antibodies
  • Table 25: Pipeline of BCMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
  • Table 26: Pipeline of CD33-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
  • Table 27: Pipeline of CD20-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
  • Table 28: Pipeline of CD123-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
  • Table 29: Pipeline of PSMA-Targeted Bispecific T-Cell and NK Cell Engaging Antibodies
  • Table 30: Financing Sources of Technology Companies with Bispecific T-Cell and NK Cell Engaging Antibody Technologies
  • Table 31: Amgen's Bispecific T-Cell Engager Pipeline
  • Table 32: Celgene's Clinical Pipeline of Bispecific T-Cell Redirecting Antibodies
  • Table 33: Janssen's Clinical Pipeline of T-Cell Redirecting Bispecific Antibodies
  • Table 34: Pfizer's T-cell Engaging Bispecific Antibody Pipeline
  • Table 35: Roche's Pipeline of Clinical Stage T-Cell Redirecting Bispecific Antibodies
  • Table 36: Sanofi's Bispecific T-Cell and NK Cell Engager Pipeline
  • Table 37: Abpro's Pipeline of T-Cell Engaging TetraBi Antibodies
  • Table 38: Merus' Biclonics Development Pipeline
  • Table 39: Regeneron Pharmaceuticals T-Cell Engaging Bispecific Antibody Pipeline
  • Table 40: TeneoBio's Pipeline of T-Cell Engaging Bi- and Multi-Specific Human Heavy Chain Antibodies
  • Table 41: YZY Biopharma's Pipeline of T-Cell Redirecting Bispecific Antibodies
  • Table 42: Partnering Terms for Zymeworks' Azymetric Technology
  • Table 43: Pipeline of ADAPTIR Molecules from Aptevo Therapeutics
  • Table 44: MacroGenics' Clinical Stage Pipeline of T-Cell Redirecting Bispecific DART Antibodies
  • Table 45: Xencor's Bispecific T-Cell Engaging Antibody Pipeline
  • Table 46: Generon's Pipeline of Bispecific ITab Antibodies
  • Table 47: Harpoon Therapeutics' TriTAC Pipeline
  • Table 48: Affimed Therapeutics' T-Cell and NK-Cell Engaging Antibody Pipeline
  • Table 49: GT Biopharma' Pipeline of Tri- and Tetra-Specific NK Cell Engagers
  • Table 50: Goals and Terms of Immunocore's Industry Partnering Deals for ImmTAC Technology
  • Table 51: Immuncore's Wholly Owned and Partnered Development Pipeline of ImmTACs
  • Table 52: Blincyto Global Sales
  • Table 53: Clinical Studies with IMCgp100